A01174 Summary:
| BILL NO | A01174 |
| SAME AS | No Same As |
| SPONSOR | Rodriguez |
| COSPNSR | Abinanti, Gunther, Bronson, Ramos, Cymbrowitz, Gottfried, Schimel, Arroyo, Jaffee, Perry, Weprin, Dinowitz, Rosenthal, Colton, Hooper, Zebrowski, Simanowitz, Magnarelli, Benedetto, Abbate, Aubry, Titone, Crespo, Quart, Cahill, Skoufis, Otis, Raia, Paulin, Montesano, Steck, Moya, Sepulveda |
| MLTSPNSR | Brennan, Cook, Crouch, Duprey, Englebright, Giglio, Glick, Lavine, Lentol, Lifton, Lupardo, Magee, Peoples-Stokes, Rivera, Russell, Simon, Skartados, Thiele, Titus, Weinstein, Wright |
| Add §365-i, rpld §364-j subs 25 & 25-a, rpld & add §369-ee sub 2-b, Soc Serv L; amd §§2511, 270 & 272, Pub Health L | |
| Relates to prescription drugs in Medicaid managed care programs. | |
A01174 Actions:
| BILL NO | A01174 | |||||||||||||||||||||||||||||||||||||||||||||||||
| 01/08/2015 | referred to health | |||||||||||||||||||||||||||||||||||||||||||||||||
| 02/26/2015 | reported referred to codes | |||||||||||||||||||||||||||||||||||||||||||||||||
| 04/22/2015 | reported referred to ways and means | |||||||||||||||||||||||||||||||||||||||||||||||||
| 01/06/2016 | referred to health | |||||||||||||||||||||||||||||||||||||||||||||||||
| 01/21/2016 | reported referred to codes | |||||||||||||||||||||||||||||||||||||||||||||||||
| 04/05/2016 | reported referred to ways and means | |||||||||||||||||||||||||||||||||||||||||||||||||
A01174 Memo:
Go to topNEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
submitted in accordance with Assembly Rule III, Sec 1(f)
TITLE OF BILL: An act to amend the social services law and the public health law, in relation to prescription drugs in Medicaid managed care programs; and to repeal certain provisions of the social services law, relating to payments for prescription drugs PURPOSE OR GENERAL IDEA OF BILL: To restore the "prescriber prevails" principle for all drugs, and other basic consumer protections, to prescription drug coverage under Medicaid managed care and add it to Family Health Plus and Child Health Plus. SUMMARY OF SPECIFIC PROVISIONS: This bill requires Medicaid managed care, Family Health Plus, and Child Health Plus plans to adopt the procedural protections of the Preferred Drug Program, including "pres- criber prevails," for all drugs. If a Medicaid managed care plan chooses not to do so, prescription drugs will be carved out of that plan and covered on a fee-for-service basis. Plans may also contract with the Department of Health to use the Department's PDP to carry out these functions. JUSTIFICATION: In 2005, when Medicaid prescription drug coverage was administered directly, by Medicaid, rather than being contracted out to managed care plans, the Preferred Drug Program (PDP) was established to shift prescribing to "preferred" drugs: (a) drugs that are significantly better than others in their therapeutic class and (b) other drugs in the class whose manufacturers pay the state higher rebates, The PDP included a range of procedures to protect prescribers and patients, including the rule that if, after consulting with the program, a prescriber still insists on prescribing a "non-preferred" drug, the prescriber's judgment prevails and the prescription is approved. The PDP was quite effective at shifting prescribing to the preferred drugs, while also protecting prescriber judgments on behalf of their patients. It is a model of how to effectively organize health care. However, in 2011 the Legislature went along with the Governor's budget proposal to have Medicaid managed care plans take over the prescription drug benefit. "Prescriber prevails" was included only for atypical anti- psychotics and a small list of other drug classes. In the 2013-14 enacted budget, "prescriber prevails" was protected and expanded for some categories of drugs. This bill restores the "prescri- ber prevails" principle for all drugs and other basic consumer protections for prescription drug coverage under Medicaid managed care, and adds it to Family Health Plus and Child Health Plus. PRIOR LEGISLATIVE HISTORY: A2335-C 2013-2014 FISCAL IMPLICATIONS: None.
A01174 Text:
Go to topSTATE OF NEW YORK ________________________________________________________________________ 1174 2015-2016 Regular Sessions IN ASSEMBLY January 8, 2015 ___________ Introduced by M. of A. RODRIGUEZ, ABINANTI, GUNTHER, BRONSON, RAMOS, CYMBROWITZ, BROOK-KRASNY, GOTTFRIED, SCHIMEL, ARROYO, JAFFEE, PERRY, SCARBOROUGH, WEPRIN, DINOWITZ, CAMARA, GOLDFEDER, ROSENTHAL, COLTON, HOOPER, ZEBROWSKI, SIMANOWITZ, MAGNARELLI, BENEDETTO, ABBATE, AUBRY, TITONE, ROBERTS, CRESPO, QUART, CAHILL, SKOUFIS, OTIS, RAIA, PAULIN, MONTESANO -- Multi-Sponsored by -- M. of A. BRENNAN, CLARK, COOK, CROUCH, DUPREY, GLICK, HEASTIE, LENTOL, LUPARDO, MAGEE, PEOPLES-STOKES, RUSSELL, SKARTADOS, THIELE, TITUS, WEINSTEIN, WRIGHT -- read once and referred to the Committee on Health AN ACT to amend the social services law and the public health law, in relation to prescription drugs in Medicaid managed care programs; and to repeal certain provisions of the social services law, relating to payments for prescription drugs The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The social services law is amended by adding a new section 2 365-i to read as follows: 3 § 365-i. Prescription drugs in Medicaid managed care programs. 1. 4 Definitions. As used in this section, unless the context clearly 5 requires otherwise: 6 (a) "Article" means title eleven of article five of this chapter with 7 respect to the medical assistance program, title eleven-D of article 8 five of this chapter with respect to the family health plus program, and 9 title one-A of article twenty-five of the public health law with respect 10 to the child health insurance program. 11 (b) "Clinical drug review program" means the clinical drug review 12 program under section two hundred seventy-four of the public health law. 13 (c) "Emergency condition" means a medical or behavioral condition as 14 determined by the prescriber or pharmacist, the onset of which is 15 sudden, that manifests itself by symptoms of sufficient severity, EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD00660-01-5A. 1174 2 1 including severe pain, and for which delay in beginning treatment 2 prescribed by the patient's health care practitioner would result in: 3 (i) placing the health or safety of the person afflicted with such 4 condition or other person or persons in serious jeopardy; 5 (ii) serious impairment to such person's bodily functions; 6 (iii) serious dysfunction of any bodily organ or part of such person; 7 (iv) serious disfigurement of such person; or 8 (v) severe discomfort. 9 (d) "Managed care provider" means a managed care provider under 10 section three hundred sixty-four-j of this title, a managed long term 11 care plan or other care coordination model under section forty-four 12 hundred three-f of the public health law, a family health insurance plan 13 under section three hundred sixty-nine-ee of this article (family health 14 plus program), an approved organization under title one-A of article 15 twenty-five of the public health law (child health insurance program), 16 or any other entity that provides or arranges for the provision of 17 medical assistance services and supplies to participants directly or 18 indirectly (including by referral), including case management, including 19 the managed care provider's authorized agents. 20 (e) "Non-preferred drug" means a prescription drug that requires prior 21 authorization under the participant's managed care provider. 22 (f) "Participant" means a medical assistance recipient who receives, 23 is required to receive or elects to receive his or her medical assist- 24 ance services from a managed care provider. 25 (g) "Preferred drug" means a prescription drug that is not a non-pre- 26 ferred drug under the patient's managed care provider. "Preferred drug 27 list" means a list of a managed care provider's preferred drugs. 28 (h) "Preferred drug program" means the preferred drug program estab- 29 lished under section two hundred seventy-two of the public health law. 30 (i) "Prescriber" means a health care professional authorized to 31 prescribe prescription drugs for a participant of the managed care 32 provider, acting within his or her lawful scope of practice. 33 (j) "Prescription drug" or "drug" means a drug defined in subdivision 34 seven of section sixty-eight hundred two of the education law, for which 35 a prescription is required under the federal food, drug and cosmetic 36 act. Any drug that does not require a prescription under such act, but 37 which would otherwise be eligible for reimbursement under this article 38 when ordered by a prescriber and the prescription is subject to the 39 applicable provisions of this article and paragraph (a) of subdivision 40 four of section three hundred sixty-five-a of this title. 41 (k) "Prior authorization" means a process requiring the prescriber or 42 the dispenser to verify with the participant's managed care provider 43 that the drug is appropriate for the needs of the specific patient. 44 (l) "Qualified prescription drug system" or "system" means a process 45 under this section, approved by the commissioner, through which a 46 managed care provider approves payment for a non-preferred drug for a 47 participant based on prior authorization. 48 2. Payment for prescription drugs under capitation. (a) Payment for 49 prescription drugs shall be included in the capitation payments for 50 services or supplies provided to a managed care provider's participants, 51 provided that the managed care provider pays for prescription drugs 52 under a qualified prescription drug system. Every prescription drug 53 eligible for reimbursement under this article prescribed in relation to 54 a service provided by the managed care provider shall be either a 55 preferred or non-preferred drug under the qualified prescription drug 56 system. The commissioner shall approve a managed care provider's quali-A. 1174 3 1 fied prescription drug system if it conforms to the provisions of this 2 section. 3 (b) If the managed care provider does not pay for prescription drugs 4 under a qualified prescription drug system, then payment for 5 prescription drugs for the managed care provider's patients shall not be 6 included in such capitation payments and prescription drugs shall be 7 provided for the managed care provider's participants under the 8 preferred drug program. 9 3. Qualified prescription drug system; criteria. (a) A qualified 10 prescription drug system shall promote access to the most effective 11 prescription drugs while reducing the cost of prescription drugs under 12 this article. This subdivision and subdivision four of this section 13 apply to qualified prescription drug systems. 14 (b) When a prescriber prescribes a non-preferred drug for a partic- 15 ipant, reimbursement may be denied unless prior authorization is 16 obtained, unless no prior authorization is required under this section. 17 When a prescriber prescribes a preferred drug for a participant, no 18 prior authorization shall be required for reimbursement, unless prior 19 authorization is required under the clinical drug review program. 20 (c) The commissioner shall establish performance standards for systems 21 that, at a minimum, ensure that systems provide sufficient technical 22 support and timely responses to consumers, prescribers and pharmacists. 23 (d) The commissioner shall adopt criteria for qualified prescription 24 drug systems after considering recommendations and comments received 25 from prescribers, pharmacists, participants, and organizations repres- 26 enting them. 27 (e) The managed care provider shall develop its preferred drug list 28 based initially on an evaluation of the clinical effectiveness, safety, 29 and patient outcomes, followed by consideration of the cost-effective- 30 ness of the drugs. In each therapeutic class, the managed care provider 31 shall determine whether there is one drug that is significantly more 32 clinically effective and safe, and that drug shall be included on the 33 preferred drug list without consideration of cost. If, among two or more 34 drugs in a therapeutic class, the difference in clinical effectiveness 35 and safety is not clinically significant, then cost-effectiveness may 36 also be considered in determining which drug or drugs shall be included 37 on the preferred drug list. 38 4. Prior authorization. (a) A qualified prescription drug system shall 39 make available a twenty-four hour per day, seven days per week telephone 40 call center that includes a tollfree telephone line and dedicated 41 facsimile line to respond to requests for prior authorization. The call 42 center shall include qualified health care professionals who shall be 43 available to consult with prescribers concerning prescription drugs that 44 are non-preferred drugs. A prescriber seeking prior authorization shall 45 consult with the program call line to reasonably present his or her 46 justification for the prescription and give the program's qualified 47 health care professional a reasonable opportunity to respond. 48 (b) When a patient's health care provider prescribes a non-preferred 49 drug, the prescriber shall consult with the system to confirm that in 50 his or her reasonable professional judgment, the patient's clinical 51 condition is consistent with the criteria for approval of the non-pre- 52 ferred drug. Such criteria shall include: 53 (i) the preferred drug has been tried by the patient and has failed to 54 produce the desired health outcomes; 55 (ii) the patient has tried the preferred drug and has experienced 56 unacceptable side effects;A. 1174 4 1 (iii) the patient has been stabilized on a non-preferred drug and 2 transition to the preferred drug would be medically contraindicated; or 3 (iv) other clinical indications identified by the commissioner or the 4 managed care provider for the patient's use of the non-preferred drug, 5 which shall include consideration of the medical needs of special popu- 6 lations, including children, elderly, chronically ill, persons with 7 mental health conditions, and persons affected by HIV/AIDS or Hepatitis 8 C. 9 (c) In the event that the patient does not meet the criteria in para- 10 graph (b) of this subdivision, the prescriber may provide additional 11 information to the managed care provider to justify the use of a non- 12 preferred drug. The system shall provide a reasonable opportunity for a 13 prescriber to reasonably present his or her justification of prior 14 authorization. If, after consultation with the managed care provider, 15 the prescriber, in his or her reasonable professional judgment, deter- 16 mines that the use of a non-preferred drug is warranted, the 17 prescriber's determination shall be final. 18 (d) If a prescriber meets the requirements of paragraph (b) or (c) of 19 this subdivision, the prescriber shall be granted prior authorization 20 under this section. 21 (e) In the instance where a prior authorization determination is not 22 completed within twenty-four hours of the original request, solely as 23 the result of a failure of the system (whether by action or inaction), 24 prior authorization shall be immediately and automatically granted with 25 no further action by the prescriber and the prescriber shall be notified 26 of this determination. In the instance where a prior authorization 27 determination is not completed within twenty-four hours of the original 28 request for any other reason, a seventy-two hour supply of the medica- 29 tion shall be approved by the system and the prescriber shall be noti- 30 fied of this determination. 31 (f) When, in the judgment of the prescriber or the pharmacist, an 32 emergency condition exists, and the prescriber or pharmacist notifies 33 the managed care provider that an emergency condition exists, a seven- 34 ty-two hour emergency supply of the drug prescribed shall be immediately 35 authorized by the managed care provider. 36 (g) In the event that a patient presents a prescription to a pharma- 37 cist for a prescription drug that is a non-preferred drug and for which 38 the prescriber has not obtained a prior authorization, the pharmacist 39 shall, within a prompt period based on professional judgment, notify the 40 prescriber. The prescriber shall, within a prompt period based on 41 professional judgment, either seek prior authorization or shall contact 42 the pharmacist and amend or cancel the prescription. The pharmacist 43 shall, within a prompt period based on professional judgment, notify the 44 patient when prior authorization has been obtained or denied or when the 45 prescription has been amended or cancelled. 46 (h) Once prior authorization of a prescription for a drug that is not 47 on the preferred drug list is obtained, prior authorization shall not be 48 required for any refill of the prescription. 49 (i) No prior authorization under a qualified prescription drug system 50 shall be required for: (i) atypical anti-psychotics; (ii) anti-depres- 51 sants; (iii) anti-retrovirals used in the treatment of HIV/AIDS or Hepa- 52 titis C; (iv) anti-rejection drugs used in the treatment of organ and 53 tissue transplants; and (v) any other therapeutic class for the treat- 54 ment of mental illness, HIV/AIDS or Hepatitis C, approved by the commis- 55 sioner.A. 1174 5 1 5. Clinical drug review program. In the case of a drug for which prior 2 authorization is required under the clinical drug review program, prior 3 authorization shall be obtained under the clinical drug review program 4 and not under this section. 5 6. Prescriber conduct. The managed care provider and the department 6 shall monitor the prior authorization process under a qualified 7 prescription drug system for prescribing patterns which are suspected of 8 endangering the health and safety of the patient or which demonstrate a 9 likelihood of fraud or abuse. The managed care provider and the depart- 10 ment shall take any and all actions otherwise permitted by law to inves- 11 tigate such prescribing patterns, to take remedial action and to enforce 12 applicable federal and state laws. 13 7. Use of preferred drug program. The commissioner may contract with a 14 managed care provider for the provider to use the preferred drug program 15 to provide prior authorization under the managed care provider's quali- 16 fied prescription drug system. The contract shall include terms required 17 by the commissioner to maximize savings to the Medicaid program and 18 protect the health and interests of the managed care provider's partic- 19 ipants. The contract shall provide whether the preferred drug program 20 shall use the managed care provider's lists of preferred and non-pre- 21 ferred drugs or the preferred drug list under the preferred drug 22 program, with respect to whether prior authorization is required. 23 § 2. Subdivisions 25 and 25-a of section 364-j of the social services 24 law are REPEALED. 25 § 3. Subdivision 2-b of section 369-ee of the social services law is 26 REPEALED and a new subdivision 2-b is added to read as follows: 27 2-b. Payment for prescription drugs. Payment for prescription drugs 28 shall be included in the capitated payments for services or supplies 29 provided under a family health insurance plan or provided by an employer 30 partnership for family health plus plan authorized by this section, 31 provided that the plan pays for prescription drugs under a qualified 32 prescription drug system under section three hundred sixty-five-i of 33 this article. Every prescription drug eligible for reimbursement under 34 this article prescribed in relation to a service provided by the plan 35 shall be either a preferred or non-preferred drug under the qualified 36 prescription drug system. If the plan does not pay for prescription 37 drugs under a qualified prescription drug system, then payment for 38 prescription drugs for the plan's patients shall not be included in such 39 capitation payments and prescription drugs shall be provided for the 40 approved organization's participants under the preferred drug program. 41 § 4. Section 2511 of the public health law is amended by adding a new 42 subdivision 22 to read as follows: 43 22. Payment for prescription drugs. Payment for prescription drugs 44 shall be included in the payments for services or supplies provided by 45 the approved organization, provided that the plan pays for prescription 46 drugs under a qualified prescription drug system under section three 47 hundred sixty-five-i of the social services law. Every prescription drug 48 eligible for reimbursement under this article prescribed in relation to 49 a service provided by the approved organization shall be either a 50 preferred or non-preferred drug under the qualified prescription drug 51 system. If the approved organization does not pay for prescription drugs 52 under a qualified prescription drug system, then payment for 53 prescription drugs for the approved organization's patients shall not be 54 included in such payments and prescription drugs shall be provided for 55 the approved organization's participants under the preferred drug 56 program.A. 1174 6 1 § 5. Subdivision 11 of section 270 of the public health law, as 2 amended by section 2-a of part C of chapter 58 of the laws of 2008, is 3 amended to read as follows: 4 11. "State public health plan" means the medical assistance program 5 established by title eleven of article five of the social services law 6 (referred to in this article as "Medicaid"), the elderly pharmaceutical 7 insurance coverage program established by title three of article two of 8 the elder law (referred to in this article as "EPIC"), [and] the family 9 health plus program established by section three hundred sixty-nine-ee 10 of the social services law [to the extent that section provides that the11program shall be subject to this article], and the child health insur- 12 ance program under title one-A of article twenty-five of this chapter. 13 § 6. Section 272 of the public health law is amended by adding a new 14 subdivision 12 to read as follows: 15 12. No prior authorization shall be required under the preferred drug 16 program for: 17 (a) atypical anti-psychotics; (b) anti-depressants; (c) anti-retrovi- 18 rals used in the treatment of HIV/AIDS or Hepatitis C; (d) anti-rejec- 19 tion drugs used in the treatment of organ and tissue transplants; and 20 (e) any other therapeutic class for the treatment of mental illness, 21 HIV/AIDS or Hepatitis C, recommended by the board and approved by the 22 commissioner under this section. 23 § 7. This act shall take effect on the one hundred eightieth day after 24 it shall become a law; provided, however, that section two of this act 25 shall take effect one year after this act shall become a law; and 26 provided further, that the amendments to section 369-ee of the social 27 services law made by section three of this act shall not affect the 28 repeal of such section and shall be deemed repealed therewith and 29 provided further, that the commissioner of health is immediately author- 30 ized and directed to take actions necessary to implement this act when 31 it takes effect.